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To The Editor: We commend Alashek et al for their 
excellent article [1].  However, the authors did not clarify 
why a very important high risk group was left out of their 
study, that of hemodialysis (HD) patients.   
 
Hepatitis C Virus (HCV) infection has been shown to be 
more prevalent among HD patients in developing 
countries. Hepatitis C prominently increases the burden of 
disease in the HD population. Furthermore, the longer 
patients are on HD, the more susceptible they are to HCV 
acquisition [2].  
 
More importantly in Libya, HD patients seem to have a 
higher prevalence of the disease compared to other more 
developed regions.  
Research from Libya on this issue although scant, is 
available, as evident by a relatively recent publication on 
the matter,  a study by Daw et al, conducted in Tripoli 
from 1999 to 2001 [3]. The study showed a 20.5% 
prevalence of HCV among HD patients, which is of similar 
prevalence to neighbouring Tunisia, and seems to be 
better than some of the gulf countries, where a higher 
sero-prevalence rate seems to exist within this patient 
group [2].  
 
This percentage is still unacceptable, as emphasized 
when compared to the CDC’s data which states that the 
prevalence of hepatitis C in this population averages 10%, 
any thing above clearly outlines flaws in the HD service 
[4]. 
 
Health care systems that employ strict adherence to 
universal preventive measures during HD have a low 
prevalence of HCV among their patients; an example of 
this is that the UK has a 4% prevalence of HCV among HD 
patients [2].  
 
Hemodialysis should not be a one-way street to 
acquiring a blood borne viral infection and unless clinical 
practice is changed to avoid infection risk, the overall 
disease burden for this group will only increase to their 
detriment. 
 
The current sero-prevalence status of HD patients in 
Libya needs to be studied and updated. We hope Alashek 
et al continue in their excellent work, and we recommend 
that the HD patient group in Libya is studied further, and 
any particular flaws in the provision of their care is 
identified and rectified.  
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